CME QUESTIONS FOR SEPTEMBER 2004 ISSUE OFTHE JOURNAL OF UROLOGY

1. NATURAL HISTORY OF SMALL RENAL CELL CARCINOMA: EVALUATION OF GROWTH RATE,HISTOLOGICAL GRADE, CELL PROLIFERATION AND APOPTOSIS (vol. 172, pp. 863–866)

Tumor growth rates of incidentally found small renal cell carcinomas are:

a) correlated with patient ageb) correlated with histological gradec) usually fastd) faster in male patients than in female patientse) correlated with Ki-67 positive ratio

2. EFFECT OF THE DUAL 5�-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSIONIN PROSTATE CANCER (vol. 172, pp. 915–919)

Compared to placebo, 6 weeks of therapy with dutasteride (5 mg daily) before radical prostatectomy results in:

a) more than 95% reduction of intraprostatic dihydrotestosteroneb) decreased apoptosis of prostate cancer cellsc) increased prostate cancer volumed) increased prostate cancer microvessel densitye) less than 95% reduction of intraprostatic dehydrotestosterone

3. PARTIAL CYSTECTOMY: A CONTEMPORARY REVIEW OF THE MEMORIAL SLOAN-KETTERING CANCERCENTER EXPERIENCE AND RECOMMENDATIONS FOR PATIENT SELECTION (vol. 172, pp. 878–881)

Which of the following conditions is considered a contraindication for partial cystectomy?

a) tumor in a diverticulumb) T2 transitional cell carcinoma of the bladderc) tumor located at bladder domed) diffuse carcinoma in situe) patient age more than 70 years

4. STONE FORMING RISK OF CALCIUM CITRATE SUPPLEMENTATION IN HEALTHY POSTMENOPAUSALWOMEN (vol. 172, pp. 958–961)

Which of the following statements concerning postmenopausal women is false?

a) potassium citrate supplementation increases urinary pHb) urinary oxalate excretion decreases with calcium citrate treatmentc) combined treatment with calcium citrate and potassium citrate decreases urinary calcium excretiond) urinary citrate excretion increases more significantly with potassium citrate treatment than with calcium citratee) the alkali load imposed by potassium citrate treatment is significantly more than with calcium citrate

5. INTERIM RESULTS FROM A NATIONAL MULTICENTER PHASE II TRIAL OF COMBINATION BACILLUSCALMETTE-GUERIN PLUS INTERFERON ALFA-2B FOR SUPERFICIAL BLADDER CANCER (vol. 172, pp. 888–893)

The use of combination bacillus Calmette-Guerin (BCG) plus interferon intravesical therapy:

a) has been shown to be cost-effective vs BCG alone as first line therapy after transurethral resectionb) significantly prolongs recurrence-free interval, prevents disease progression and extends survivalc) is well tolerated especially when lower dose BCG is usedd) is one of the few effective topical therapies for muscle invasive diseasee) does not require maintenance therapy to retain its best efficacy

The Journal of Urology®

Volume 172, Number 3, September 2004

1227